Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) has emerged as a leading contender among the top stocks priced under $20. On September 19, the company reached a significant achievement: the National Comprehensive Cancer Network (NCCN) revised its Clinical Practice Guidelines in Oncology to include Revuforj (revumenib) for acute myeloid leukemia (AML).
Revumenib has received a Category 2A recommendation to treat relapsed or refractory (R/R) AML featuring an NPM1 mutation/mNPM1. This recommendation follows promising results from the AUGMENT-101 clinical trial, which were published in the journal Blood in 2025. Previously, revumenib was also listed as a Category 2A treatment option for R/R acute leukemia with a KMT2A rearrangement in the NCCN Guidelines for AML and acute lymphoblastic leukemia (ALL).
Syndax has filed a supplemental New Drug Application (sNDA) seeking approval for revumenib in treating R/R mNPM1 AML. The US FDA has designated the sNDA for Priority Review and is evaluating it through the Real-Time Oncology Review (RTOR) program, aiming for a Prescription Drug User Fee Act (PDUFA) target action date on October 25 this year.
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) operates as a commercial-stage biopharmaceutical firm focusing on cancer therapies.
While we recognize the investment potential of SNDX, we believe some AI stocks present even greater upside with reduced downside risks. If you’re interested in discovering an extremely undervalued AI stock poised to benefit from the Trump-era tariffs and the trend of onshoring, check out our complimentary report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article originally appears on Insider Monkey.
